TSplus Cheers on “Sisters In Rose” as the Adventure Begins in the Trophée Roses des Sables 2025 
Doubleview Gold Corp Announces 320-Meter Eastward Extension at the Hat Polymetallic Deposit, Expanding Mineralized Volume and Remaining Open 
U.S. Polo Assn. Wins Gold and Silver Stevie Awards at the 2025 International Business Awards in Lisbon, Portugal 
CITIC Telecom CPC Garners CAHK STAR Award 2025 Again Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful results These…
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful results These…
QIAGEN N.V. to release results for Q2 2023 and hold webcast
Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) — QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock…
QIAGEN N.V. to release results for Q2 2023 and hold webcast
Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) — QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock…
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement…
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement…
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) — Overland ADCT…
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) — Overland ADCT…
Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers
BOSTON, July 24, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology…
Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers
BOSTON, July 24, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology…
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical…
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical…
FibroGen to Report Second Quarter 2023 Financial Results
SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) will announce its…
FibroGen to Report Second Quarter 2023 Financial Results
SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) will announce its…
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
Common stock and warrants of combined company will be listed on the New York Stock…
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
Common stock and warrants of combined company will be listed on the New York Stock…
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
Linda Burkly Editas Medicine today announced the appointment of Linda C. Burkly, Ph.D., as the…
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
Linda Burkly Editas Medicine today announced the appointment of Linda C. Burkly, Ph.D., as the…
Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test
New Findings Support Development of Racemic Tianeptine and (S)-Tianeptine (Estianeptine) as First-in-Class Oral Therapies in…